Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence

Denis Vivien; Maxime Gauberti; Axel Montagne; Gilles Defer; Emmanuel Touzé

doi:10.1038/jcbfm.2011.127

Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence

Denis Vivien, Maxime Gauberti, Axel Montagne, Gilles Defer, Emmanuel Touzé

Research output: Contribution to journal › Review article › peer-review

Abstract

About 15 million strokes occur each year worldwide. As the number one cause of morbidity and acquired disability, stroke is a major drain on public health-care funding, due to long hospital stays followed by ongoing support in the community or nursing-home care. Although during the last 10 years we have witnessed a remarkable progress in the understanding of the pathophysiology of ischemic stroke, reperfusion induced by recombinant tissue-type plasminogen activator (tPA-Actilyse) remains the only approved acute treatment by the health authorities. The objective of the present review is to provide an overview of our present knowledge about the impact of tPA on the neurovascular unit during acute ischemic stroke.

Original language	English
Pages (from-to)	2119-34
Number of pages	16
Journal	Journal of Cerebral Blood Flow and Metabolism
Volume	31
Issue number	11
DOIs	https://doi.org/10.1038/jcbfm.2011.127
Publication status	Published - Nov 2011

Keywords

Acute Disease
Aging/pathology
Animals
Blood-Brain Barrier/drug effects
Brain/blood supply
Drug Administration Schedule
Fibrinolytic Agents/administration & dosage
Humans
Microvessels/drug effects
Stroke/drug therapy
Thrombolytic Therapy/methods
Tissue Plasminogen Activator/administration & dosage

Access to Document

10.1038/jcbfm.2011.127

Cite this

@article{c24a291069e24690a5e37d3978c81969,

title = "Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence",

abstract = "About 15 million strokes occur each year worldwide. As the number one cause of morbidity and acquired disability, stroke is a major drain on public health-care funding, due to long hospital stays followed by ongoing support in the community or nursing-home care. Although during the last 10 years we have witnessed a remarkable progress in the understanding of the pathophysiology of ischemic stroke, reperfusion induced by recombinant tissue-type plasminogen activator (tPA-Actilyse) remains the only approved acute treatment by the health authorities. The objective of the present review is to provide an overview of our present knowledge about the impact of tPA on the neurovascular unit during acute ischemic stroke.",

keywords = "Acute Disease, Aging/pathology, Animals, Blood-Brain Barrier/drug effects, Brain/blood supply, Drug Administration Schedule, Fibrinolytic Agents/administration & dosage, Humans, Microvessels/drug effects, Stroke/drug therapy, Thrombolytic Therapy/methods, Tissue Plasminogen Activator/administration & dosage",

author = "Denis Vivien and Maxime Gauberti and Axel Montagne and Gilles Defer and Emmanuel Touz{\'e}",

year = "2011",

month = nov,

doi = "10.1038/jcbfm.2011.127",

language = "English",

volume = "31",

pages = "2119--34",

journal = "Journal of Cerebral Blood Flow and Metabolism",

issn = "1559-7016",

publisher = "LIPPINCOTT-RAVEN PUBL",

number = "11",

}

TY - JOUR

T1 - Impact of tissue plasminogen activator on the neurovascular unit

T2 - from clinical data to experimental evidence

AU - Vivien, Denis

AU - Gauberti, Maxime

AU - Montagne, Axel

AU - Defer, Gilles

AU - Touzé, Emmanuel

PY - 2011/11

Y1 - 2011/11

N2 - About 15 million strokes occur each year worldwide. As the number one cause of morbidity and acquired disability, stroke is a major drain on public health-care funding, due to long hospital stays followed by ongoing support in the community or nursing-home care. Although during the last 10 years we have witnessed a remarkable progress in the understanding of the pathophysiology of ischemic stroke, reperfusion induced by recombinant tissue-type plasminogen activator (tPA-Actilyse) remains the only approved acute treatment by the health authorities. The objective of the present review is to provide an overview of our present knowledge about the impact of tPA on the neurovascular unit during acute ischemic stroke.

AB - About 15 million strokes occur each year worldwide. As the number one cause of morbidity and acquired disability, stroke is a major drain on public health-care funding, due to long hospital stays followed by ongoing support in the community or nursing-home care. Although during the last 10 years we have witnessed a remarkable progress in the understanding of the pathophysiology of ischemic stroke, reperfusion induced by recombinant tissue-type plasminogen activator (tPA-Actilyse) remains the only approved acute treatment by the health authorities. The objective of the present review is to provide an overview of our present knowledge about the impact of tPA on the neurovascular unit during acute ischemic stroke.

KW - Acute Disease

KW - Aging/pathology

KW - Animals

KW - Blood-Brain Barrier/drug effects

KW - Brain/blood supply

KW - Drug Administration Schedule

KW - Fibrinolytic Agents/administration & dosage

KW - Humans

KW - Microvessels/drug effects

KW - Stroke/drug therapy

KW - Thrombolytic Therapy/methods

KW - Tissue Plasminogen Activator/administration & dosage

U2 - 10.1038/jcbfm.2011.127

DO - 10.1038/jcbfm.2011.127

M3 - Review article

C2 - 21878948

VL - 31

SP - 2119

EP - 2134

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 1559-7016

IS - 11

ER -

Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence

Abstract

Keywords

Access to Document

Fingerprint

Cite this